RxDoctor Payments Data

Anthony Giardina, DO

Family Medicine · Kingston, PANPI 1003879560

Payments from drug & device makers

$13,138in general payments, 2019–2025

Across 478 payments — averaging $27.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$3K
  • AstraZeneca$2K
  • Bayer$2K
  • Boehringer Ingelheim$2K
  • Esperion Therapeutics, Inc.$892
  • Amgen$452
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$13,127100%
  • Education$110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,138 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$22,150
Medicare patients
36
Services billed
273

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin82$55,732
Trelegy ElliptaFluticasone/Umeclidin/Vilanter62$46,308
TrulicityDulaglutide30$36,373
KerendiaFinerenone41$35,607
Breztri AerosphereBudesonide/Glycopyr/Formoterol36$27,743
EliquisApixaban35$22,198
Stiolto RespimatTiotropium Br/Olodaterol Hcl44$20,871
Spiriva RespimatTiotropium Bromide22$13,549
FarxigaDapagliflozin Propanediol20$11,612
LinzessLinaclotide18$9,637
Lantus SolostarInsulin Glargine,hum.Rec.Anlog40$2,803
Albuterol Sulfate HfaAlbuterol Sulfate62$1,610
Ventolin HfaAlbuterol Sulfate25$1,351
Losartan Potassium151$1,218
Montelukast Sodium86$1,180

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat$1,831$90,152148 claims
GSKTrelegy Ellipta$2,826$46,30862 claims
AstraZenecaBreztri Aerosphere, Farxiga$2,389$39,35556 claims
Lilly USA, LLCTrulicity$445$36,37330 claims
BayerKerendia$2,291$35,60741 claims
AbbVieLinzess$398$9,63718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Kingston

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →